fluconazole has been researched along with Bleeding in 5 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bleeding safety in relation to use of systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is insufficiently explored, despite clinical relevance and several reports suggesting associations." | 8.12 | Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. ( Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C, 2022) |
| " Metronidazole and fluconazole inhibit the metabolism of warfarin by blocking cytochrome P-450 2C9 (CYP-2C9), the major metabolic pathway of warfarin, with the end result being dramatic increases in patients' international normalized ratios (INRs) and potentially fatal bleeding." | 4.91 | Three Serious Drug Interactions that Every Dentist Should Know About. ( Hersh, EV; Moore, PA, 2015) |
| "Bleeding safety in relation to use of systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is insufficiently explored, despite clinical relevance and several reports suggesting associations." | 4.12 | Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. ( Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holt, A | 1 |
| Strange, JE | 1 |
| Rasmussen, PV | 1 |
| Blanche, P | 1 |
| Nouhravesh, N | 1 |
| Jensen, MH | 1 |
| Schjerning, AM | 1 |
| Schou, M | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, GH | 1 |
| Hansen, ML | 1 |
| McGettigan, P | 1 |
| Lamberts, M | 1 |
| Shimoda, T | 1 |
| Watanabe, A | 1 |
| Wasmann, R | 1 |
| Brüggemann, R | 1 |
| Hersh, EV | 1 |
| Moore, PA | 1 |
| Allegue, F | 1 |
| de Lis, MP | 1 |
| Pérez-Alvarez, R | 1 |
1 review available for fluconazole and Bleeding
| Article | Year |
|---|---|
Three Serious Drug Interactions that Every Dentist Should Know About.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Bradycardia; Cytochrome P-450 | 2015 |
4 other studies available for fluconazole and Bleeding
| Article | Year |
|---|---|
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran | 2022 |
Apixaban for Atrial Fibrillation and Systemic Fluconazole: Bleeding Risk and Possible Preventative Measures.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Fluconazole; Hemorrhage; Humans; Pyrazole | 2022 |
A stitch in time saves nine.
Topics: Fluconazole; Hemorrhage; Humans; Warfarin | 2019 |
Primary cutaneous cryptococcosis presenting as a whitlow.
Topics: Aged; Antifungal Agents; Cryptococcosis; Dermatomycoses; Fluconazole; Hand Dermatoses; Hemorrhage; H | 2007 |